{
    "Trade/Device Name(s)": [
        "Randox Immunoassay Speciality Control (l) Levels 1, 2 and 3",
        "Immunoassay Speciality Control (l) Levels 1, 2 and 3"
    ],
    "Submitter Information": "Randox Laboratories Limited",
    "510(k) Number": "K130337",
    "Predicate Device Reference 510(k) Number(s)": [
        "K043108"
    ],
    "Regulatory Class": "Class I",
    "Product Code(s)": [
        "JJY"
    ],
    "Summary Letter Date": "April 12, 2013",
    "Summary Letter Received Date": "May 20, 2013",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 862.1660"
    ],
    "Regulation Name(s)": [
        "Quality control material (assayed and unassayed)"
    ],
    "Analyte Class(es)": [
        "chemistry",
        "endocrine",
        "immunology"
    ],
    "Analyte(s)": [
        "1-25 Dihydroxy Vitamin D (1-25 (OH)2 Vitamin D)",
        "25 Hydroxy Vitamin D (25 OH Vitamin D)",
        "Anti-Thyroglobulin (Anti TG)",
        "Anti-Thyroid Peroxidase (Anti TPO)",
        "C-Peptide",
        "Insulin Like Growth Factor (IGF 1)",
        "Parathyroid Hormone (PTH)",
        "Procalcitonin",
        "Insulin",
        "Osteocalcin"
    ],
    "Specimen Type(s)": [
        "Human serum"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [],
    "Method(s)/Technology(ies)": [],
    "Methodologies": [],
    "Submission Type(s)": [
        "Control",
        "Quality control material"
    ],
    "Document Summary": "FDA 510(k) summary for Randox Immunoassay Speciality Control (l) Levels 1, 2 and 3 as assayed quality control material for precision monitoring of laboratory immunoassay procedures.",
    "Indications for Use Summary": "Intended for in vitro diagnostic use as assayed quality control material to monitor the precision of laboratory testing procedures for several immunoassay analytes including vitamin D metabolites, autoantibodies, peptide hormones, and protein markers.",
    "fda_folder": "Clinical Chemistry"
}